OR Royalties Inc. (NYSE:OR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of OR Royalties Inc. (NYSE:OR) have received an average rating of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $38.25.

OR has been the subject of several analyst reports. Scotiabank boosted their target price on shares of OR Royalties from $41.00 to $51.00 and gave the company a “sector perform” rating in a research note on Monday, January 26th. TD Securities reaffirmed a “hold” rating on shares of OR Royalties in a research note on Monday, February 23rd. Canadian Imperial Bank of Commerce reiterated an “outperform” rating on shares of OR Royalties in a report on Wednesday, February 4th. Weiss Ratings reissued a “buy (b)” rating on shares of OR Royalties in a research report on Monday, December 29th. Finally, Wall Street Zen raised shares of OR Royalties from a “buy” rating to a “strong-buy” rating in a research note on Saturday.

Institutional Investors Weigh In On OR Royalties

Several hedge funds have recently made changes to their positions in OR. Caitong International Asset Management Co. Ltd acquired a new position in OR Royalties in the fourth quarter valued at $206,000. Elliott Investment Management L.P. boosted its stake in OR Royalties by 42.7% in the 4th quarter. Elliott Investment Management L.P. now owns 3,111,000 shares of the basic materials company’s stock worth $110,098,000 after buying an additional 930,849 shares during the last quarter. XTX Topco Ltd purchased a new stake in OR Royalties in the 4th quarter valued at about $832,000. Yaupon Capital Management LP increased its stake in shares of OR Royalties by 5.6% during the 4th quarter. Yaupon Capital Management LP now owns 205,228 shares of the basic materials company’s stock valued at $7,270,000 after acquiring an additional 10,809 shares during the last quarter. Finally, Oxford Asset Management LLP lifted its holdings in shares of OR Royalties by 103.6% during the 4th quarter. Oxford Asset Management LLP now owns 26,977 shares of the basic materials company’s stock worth $955,000 after acquiring an additional 13,724 shares during the period. Institutional investors and hedge funds own 68.52% of the company’s stock.

OR Royalties Stock Performance

OR Royalties stock opened at $32.89 on Monday. OR Royalties has a fifty-two week low of $18.99 and a fifty-two week high of $48.06. The company has a market capitalization of $6.17 billion, a price-to-earnings ratio of 30.17 and a beta of 0.75. The stock has a fifty day moving average of $42.40 and a two-hundred day moving average of $37.91.

OR Royalties (NYSE:OR) last issued its quarterly earnings data on Wednesday, February 18th. The basic materials company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.01. The business had revenue of $90.47 million for the quarter, compared to the consensus estimate of $90.80 million. OR Royalties had a return on equity of 12.73% and a net margin of 74.30%. On average, analysts forecast that OR Royalties will post 0.62 EPS for the current fiscal year.

OR Royalties Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Tuesday, March 31st will be paid a dividend of $0.055 per share. This represents a $0.22 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Tuesday, March 31st. OR Royalties’s dividend payout ratio is currently 20.18%.

OR Royalties Company Profile

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.